Clinical Pre-screening Protocol for Ovarian Cancer
Recruiting now
Conditions studied: Ovarian Cancer
In brief
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Key facts
- Study ID
- NCT03877796
- Run by
- Allarity Therapeutics
- People needed
- 60
- Starts
- 2019-04-11
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Patients with histological confirmed epithelia ovarian cancer
- Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
- Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
- FFPE tumor tissue available
You may not qualify if…
- Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
- Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Where it is running
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- University of New Mexico Comprehensive Cancer — Albuquerque, New Mexico, United States (enrolling)
- The Blavatnik Family-Chelsea Medical Center at Mount Sinai — New York, New York, United States (enrolling)
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma, United States (enrolling)
- University Medical Center Cancer Center — Lubbock, Texas, United States (enrolling)
- Swedish Center for Research and Innovation — Seattle, Washington, United States (enrolling)
- Beatson West of Scotland Cancer Centre — Glasgow, Scotland, United Kingdom (enrolling)
- Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital — London, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.